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Th e quality of scientifi c data supporting the use of antiangiogéncios 
(AntiVGEF) in retinal diseases is indisputable.1 Th is has resulted in an 
explosive spread for the three approved indications: macular choroidal 
neovascular membrane, macular edema in diabetic retinopathy and vein 
occlusion. Th ere are is also large volume of reports of its benefi ts in almost 
all neovascular and ischemic diseases of the retina.2
Th e economic implications for the health sector are important and this 
explosion have caused concerns in ophthalmologists in many countries and 
the health authorities have had to take actions on it.
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Th ere is an accepted methodology for 
assessing the cost-benefi t of treatment and it 
has been implemented by NICE (National 
Institute for Health and Care Excellence)3 of 
England. Th e vision years gained with treatment 
are equated to a quantitative table equivalence 
of quality. Th e numerical equivalent of the 
estimated vision without treatment is subtracted 
and the estimation of the years gained with 
treatment life is obtained. ( QALY, Quality 
Adjusted Life of Years). NICE has estimated 
that in England, the system is able to invest 
about US $ 50,000 for each year of life gained 
with quality treatment. If the equivalence of 
per capita income and health expenditures 
is made for Colombia the value could be 
between US$7,000 and US$15.000. When 
this methodology is applied  for most of the 
treated cases in Colombia, it can be considered 
that costs are justifi ed by benefi ts. However in 
some cases where the benefi ts are marginal, 
cost-benefi t ratio is not justifi able.
It has been a tradition in medicine that 
the physician’s responsibility is limited to 
individual action with the patient. Codes 
of ethics and laws governing the exercise 
emphasize the personal relationship and 
the variables that determine it. However, 
it is increasingly evident that every medical 
decision has economic implications. To the 
extent that technology and the diagnostic 
and therapeutic resources become more 
sophisticated, the medical act has increasingly 
impact on the economy of a society. Doctors 
tend to think that their ethical responsibility is 
limited only to the individual benefi t of each 
patient and broader economic implications 
of their decisions do not have to aff ect them. 
Th e truth is that in any society resources for 
health are limited; therefore, one of the ethical 
implications is that resources that are used 
in a not justifi ed manner on one hand, may 
not be used in higher return alternative to 
health outcomes in the other side. Doctors 
may consider their duty to fi ght for a patient 
of 80 years to receive a liver transplant at a 
cost of US $ 200,000 for the patient’s right 
to live two or three years. But if the decision 
means that 20,000 children will not receive 
a US $10 vaccine and so 1000 of them get 
sick and 100 die, the ethical balance is not 
very positive.
It is essential to disseminate the concept 
of dual responsibility of the medical act: with 
the patient and social resources. For decisions 
that necessarily involve an cost-opportunity : 
each a decision made is giving up the benefi ts 
that would have provided the alternatives. It 
is therefore necessary to make conscientious, 
explicit and clear that medical professionals 
not only decide on the health of patients, but 
decides on the resources of the health sector 
and indirectly on the resources of society.
Comparative studies with good level 
of evidence, aimed to evaluate Avastin vs. 
Lucentis vs Eylea, have shown no signifi cant 
diff erences in either results or side eff ects. Small 
diff erences in some studies, with confl icting 
diff erences may invalidate others. In any case, 
the key question remains if a little diff erence is 
fi nded, it may be due to random diff erences. 
Only with the selling price of Lucentis in 
Colombia in 2012, one can calculate that if the 
treatment had been made with an equivalent 
cost by 10%, it would have achieved savings 
of 30,000 million pesos.
Th e amount of information available is 
overwhelming and how to interpret it may 
be subject to bias and commercial infl uences. 
Colombia differences in rates of use of 
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antiangiogenic, by retina specialist and city, 
suggests that there is no unifi ed scientifi c 
criteria or there are factors other than strict 
medical indication that infl uence practices.5
There fore  the  re spons ib i l i ty  o f 
ophthalmologists is to do their best to establish 
guidelines or protocols to guide the management 
of common diseases with a criterion of cost-
benefi t or cost-eff ective. To pretend that ethics 
is not to mention money and that commercial 
infl uences do not aff ect doctors, is to bury the 
head in the ground.
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